Pub Date : 2023-12-04DOI: 10.1101/2023.12.04.23299128
Cecilia Magnusson, Per Augustsson, Eva Undvall Anand, Andreas Lenshof, Andreas Josefsson, Karin Welen, Anders Bjartell, Yvonne Ceder, Hans Lilja, Thomas Laurell
Background: There are important unmet clinical needs to develop cell enrichment technologies to enable unbiased label-free isolation of both single cell and clusters of circulating tumor cells (CTCs) manifesting heterogeneous lineage specificity. Here, we report a pilot study based on microfluidic acoustophoresis enrichment of CTCs using the CellSearch CTC assay as a reference modality. Methods: Acoustophoresis uses an ultrasonic standing wave field to separate cells based on biomechanical properties (size, density, and compressibility) resulting in inherently label-free and epitope-independent cell enrichment. Following red blood cell lysis and paraformaldehyde fixation, 6 mL of whole blood from 12 patients with metastatic prostate cancer and 20 healthy controls were processed with acoustophoresis and subsequent image cytometry. Results: Acoustophoresis enabled enrichment and characterization of phenotypic CTCs (EpCAM+, Cytokeratin+, DAPI+, CD45-/CD66b-) in all patients with metastatic prostate cancer and detected CTC-clusters composed of only CTCs or heterogenous aggregates of CTCs clustered with various types of white blood cells in 9 out of 12 patients. By contrast, CellSearch did not detect any CTC-clusters, but detected comparable numbers of phenotypic CTCs as acoustophoresis, with trends of finding higher number of CTCs using acoustophoresis. Conclusion: Our preliminary data indicate that acoustophoresis provides excellent possibilities to detect and characterize CTC-clusters as a putative marker of metastatic disease and outcomes. Moreover, acoustophoresis enables sensitive label-free enrichment of cells with epithelial phenotype in blood and offers opportunities to detect and characterize CTCs undergoing epithelial-to-mesenchymal transitioning and lineage plasticity.
{"title":"Acoustic enrichment of heterogenous circulating tumor cells and clusters from patients with metastatic prostate cancer","authors":"Cecilia Magnusson, Per Augustsson, Eva Undvall Anand, Andreas Lenshof, Andreas Josefsson, Karin Welen, Anders Bjartell, Yvonne Ceder, Hans Lilja, Thomas Laurell","doi":"10.1101/2023.12.04.23299128","DOIUrl":"https://doi.org/10.1101/2023.12.04.23299128","url":null,"abstract":"Background: There are important unmet clinical needs to develop cell enrichment technologies to enable unbiased label-free isolation of both single cell and clusters of circulating tumor cells (CTCs) manifesting heterogeneous lineage specificity. Here, we report a pilot study based on microfluidic acoustophoresis enrichment of CTCs using the CellSearch CTC assay as a reference modality. Methods: Acoustophoresis uses an ultrasonic standing wave field to separate cells based on biomechanical properties (size, density, and compressibility) resulting in inherently label-free and epitope-independent cell enrichment. Following red blood cell lysis and paraformaldehyde fixation, 6 mL of whole blood from 12 patients with metastatic prostate cancer and 20 healthy controls were processed with acoustophoresis and subsequent image cytometry. Results: Acoustophoresis enabled enrichment and characterization of phenotypic CTCs (EpCAM+, Cytokeratin+, DAPI+, CD45-/CD66b-) in all patients with metastatic prostate cancer and detected CTC-clusters composed of only CTCs or heterogenous aggregates of CTCs clustered with various types of white blood cells in 9 out of 12 patients. By contrast, CellSearch did not detect any CTC-clusters, but detected comparable numbers of phenotypic CTCs as acoustophoresis, with trends of finding higher number of CTCs using acoustophoresis. Conclusion: Our preliminary data indicate that acoustophoresis provides excellent possibilities to detect and characterize CTC-clusters as a putative marker of metastatic disease and outcomes. Moreover, acoustophoresis enables sensitive label-free enrichment of cells with epithelial phenotype in blood and offers opportunities to detect and characterize CTCs undergoing epithelial-to-mesenchymal transitioning and lineage plasticity.","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138510429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background Intravenous immune checkpoint inhibition achieves a 40% three-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Yet only half of early responders will continue to be disease free by 12 months, and resistance mechanisms are poorly defined.
{"title":"A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer","authors":"Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J. Meeks","doi":"10.1101/2023.11.28.23299093","DOIUrl":"https://doi.org/10.1101/2023.11.28.23299093","url":null,"abstract":"<strong>Background</strong> Intravenous immune checkpoint inhibition achieves a 40% three-month response in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). Yet only half of early responders will continue to be disease free by 12 months, and resistance mechanisms are poorly defined.","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138510799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-24DOI: 10.1101/2022.10.23.22281406
Chenxi Pan, YI He, He Wang, Yang Yu, Lu Li, Lingling Huang, Mengge Lv, Weigang Ge, Bo Yang, Yaoting Sun, Tiannan Guo, Zhiyu Liu
Background: Prostate cancer (PCa) is the second most prevalent malignancy and the fifth cause of cancer-related deaths in men. A crucial challenge is identifying the population at risk of rapid progression from hormone-sensitive PCa (HSPC) to the lethal castration-resistant PCa (CRPC). Methods: We collected 78 HSPC biopsies and measured their proteomes using pressure cycling technology and a pulsed data-independent acquisition pipeline. The proteomics data and clinical metadata were used to generate models for classifying HSPC patients and predicting the development of each case. Results: We quantified 7,961 proteins using the HSPC biopsies. A total of 306 proteins were differentially expressed between patients with a long- or short-term progression to CRPC. Using a random forest model, we identified ten proteins that significantly discriminated long- from short-term cases, which were used to classify PCa patients with an 86% accuracy. Next, two clinical parameters (Gleason sum and total PSA) and five proteins (DPT, ARGEF1, UTP23, CMAS, and ANAPC4) were found to be significantly associated with rapid disease progression. A nomogram model using these seven features was generated for stratifying patients into groups with significant progression disparities. Conclusion: We identified proteins associated with a fast progression to CRPC and an unfavorable prognosis. Based on these proteins, our machine learning and nomogram models stratified HSPC into high- and low-risk groups and predict their prognoses. These tools may aid clinicians in predicting the progression of patients, guiding individualized clinical management and decisions.
{"title":"Identifying patients with rapid progression from hormone-sensitive to castration-resistant prostate cancer: a retrospective study","authors":"Chenxi Pan, YI He, He Wang, Yang Yu, Lu Li, Lingling Huang, Mengge Lv, Weigang Ge, Bo Yang, Yaoting Sun, Tiannan Guo, Zhiyu Liu","doi":"10.1101/2022.10.23.22281406","DOIUrl":"https://doi.org/10.1101/2022.10.23.22281406","url":null,"abstract":"Background: Prostate cancer (PCa) is the second most prevalent malignancy and the fifth cause of cancer-related deaths in men. A crucial challenge is identifying the population at risk of rapid progression from hormone-sensitive PCa (HSPC) to the lethal castration-resistant PCa (CRPC).\u0000Methods: We collected 78 HSPC biopsies and measured their proteomes using pressure cycling technology and a pulsed data-independent acquisition pipeline. The proteomics data and clinical metadata were used to generate models for classifying HSPC patients and predicting the development of each case.\u0000Results: We quantified 7,961 proteins using the HSPC biopsies. A total of 306 proteins were differentially expressed between patients with a long- or short-term progression to CRPC. Using a random forest model, we identified ten proteins that significantly discriminated long- from short-term cases, which were used to classify PCa patients with an 86% accuracy. Next, two clinical parameters (Gleason sum and total PSA) and five proteins (DPT, ARGEF1, UTP23, CMAS, and ANAPC4) were found to be significantly associated with rapid disease progression. A nomogram model using these seven features was generated for stratifying patients into groups with significant progression disparities.\u0000Conclusion: We identified proteins associated with a fast progression to CRPC and an unfavorable prognosis. Based on these proteins, our machine learning and nomogram models stratified HSPC into high- and low-risk groups and predict their prognoses. These tools may aid clinicians in predicting the progression of patients, guiding individualized clinical management and decisions.","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138510428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-13DOI: 10.1101/2022.10.13.22281046
Razman Arabzadeh Bahri, Saba Maleki, Arman Shafiee, Parnian Shobeiri
Objectives: To determine whether the outcomes of ultrasound-guided percutaneous nephrolithotomy (UG-PCNL), an alternative to traditional fluoroscopy-guided percutaneous nephrolithotomy (FG-PCNL), are comparable. Methods: A systematic search of PubMed, Embase, and the Cochrane Library was carried out to discover investigations comparing UG-PCNL to FG-PCNL, and accordingly, a meta-analysis of those studies was performed. The primary outcomes included the stone-free rate (SFR), overall complications based on Clavien-Dindo classification, duration of surgery, duration of patients’ hospitalization, and hemoglobin (Hb) drop during the surgery. All statistical analyses and visualizations were implemented utilizing R software. Results: Nineteen studies, including eight randomized clinical trials (RCTs) and eleven observational cohorts, comprising 3016 patients (1521 UG-PCNL patients) and comparing UG-PCNL with FG-PCNL met the inclusion criteria of the current study. Considering SFR, overall complications, duration of surgery, duration of hospitalization, and Hb drop, our meta-analysis revealed no statistically significant difference between UG-PCNL and FG-PCNL patients, with p-values of 0.29, 0.47, 0.98, 0.28, and 0.42, respectively. Significant differences were discovered between UG-PCNL and FG-PCNL patients in terms of the length of time they were exposed to radiation (p-value< 0.0001). Moreover, FG-PCNL had shorter access time than UG-PCNL (p-value= 0.04). Conclusion: UG-PCNL provides the advantage of requiring less radiation exposure while being just as efficient as FG-PCNL; thus, this study suggests prioritizing the use of UG-PCNL.
{"title":"Ultrasound versus fluoroscopy as imaging guidance for percutaneous nephrolithotomy: A systematic review and meta-analysis","authors":"Razman Arabzadeh Bahri, Saba Maleki, Arman Shafiee, Parnian Shobeiri","doi":"10.1101/2022.10.13.22281046","DOIUrl":"https://doi.org/10.1101/2022.10.13.22281046","url":null,"abstract":"Objectives: To determine whether the outcomes of ultrasound-guided percutaneous nephrolithotomy (UG-PCNL), an alternative to traditional fluoroscopy-guided percutaneous nephrolithotomy (FG-PCNL), are comparable.\u0000Methods: A systematic search of PubMed, Embase, and the Cochrane Library was carried out to discover investigations comparing UG-PCNL to FG-PCNL, and accordingly, a meta-analysis of those studies was performed. The primary outcomes included the stone-free rate (SFR), overall complications based on Clavien-Dindo classification, duration of surgery, duration of patients’ hospitalization, and hemoglobin (Hb) drop during the surgery. All statistical analyses and visualizations were implemented utilizing R software.\u0000Results: Nineteen studies, including eight randomized clinical trials (RCTs) and eleven observational cohorts, comprising 3016 patients (1521 UG-PCNL patients) and comparing UG-PCNL with FG-PCNL met the inclusion criteria of the current study. Considering SFR, overall complications, duration of surgery, duration of hospitalization, and Hb drop, our meta-analysis revealed no statistically significant difference between UG-PCNL and FG-PCNL patients, with p-values of 0.29, 0.47, 0.98, 0.28, and 0.42, respectively. Significant differences were discovered between UG-PCNL and FG-PCNL patients in terms of the length of time they were exposed to radiation (p-value< 0.0001). Moreover, FG-PCNL had shorter access time than UG-PCNL (p-value= 0.04).\u0000Conclusion: UG-PCNL provides the advantage of requiring less radiation exposure while being just as efficient as FG-PCNL; thus, this study suggests prioritizing the use of UG-PCNL.","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138510430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-28DOI: 10.1101/2022.06.27.22276955
Matthew H V Byrne, Fanourios Georgiades, Alexander Light, Catherine E Lovegrove, Catherine Dominic, Josephine Rahman, Senthooran Kathiravelupillai, Tobias Klatte, Kasra Saeb-Parsy, Rajeev Kumar, Sarah Howles, Grant D Stewart, Ben Turney, Oliver Wiseman, the COVID Stones Collaborative
Objectives To determine if management of ureteric stones in the United Kingdom changed during the COVID-19 pandemic and whether this affected patient outcomes.
{"title":"Impact of COVID-19 on the management and outcomes of ureteric stones in the UK: a multicentre retrospective study","authors":"Matthew H V Byrne, Fanourios Georgiades, Alexander Light, Catherine E Lovegrove, Catherine Dominic, Josephine Rahman, Senthooran Kathiravelupillai, Tobias Klatte, Kasra Saeb-Parsy, Rajeev Kumar, Sarah Howles, Grant D Stewart, Ben Turney, Oliver Wiseman, the COVID Stones Collaborative","doi":"10.1101/2022.06.27.22276955","DOIUrl":"https://doi.org/10.1101/2022.06.27.22276955","url":null,"abstract":"<strong>Objectives</strong> To determine if management of ureteric stones in the United Kingdom changed during the COVID-19 pandemic and whether this affected patient outcomes.","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138537730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-05-19DOI: 10.1101/2022.05.18.22275252
Agus Rizal Ardy Hariandy Hamid, Yasmina Zahra Syadza, Oliver Emmanuel Yausep, Roberto Bagaskara Indy Christanto, Bayu Hernawan Rahmat Muharia, Chaidir Arif Mochtar
Bladder cancer is one of the most frequent cancers of the urinary tract, associated with high recurrence rates and metastasis. Cancer stem cells (CSCs) are a subpopulation of cancer cells characterized by high self-renewal and differentiation capacities, resulting in increased cancer recurrence, larger tumor size, higher rates of metastasis, higher resistance to treatment, and overall poorer prognosis. This study aimed to evaluate the role of CSCs as a prognostic tool to predict the risks of metastasis and recurrence in bladder cancer. A literature search was conducted across seven databases from January 2000 to February 2022 for clinical studies investigating the use of CSCs to determine the prognosis of bladder cancer. The following keywords were used: (“Bladder Cancer” OR “Transitional Cell Carcinoma” OR “Urothelial Carcinoma”) AND (“Stem Cell” OR “Stem Gene”) AND (“Metastasis” OR “Recurrence”). A total of 12 studies were deemed eligible for inclusion. SOX2, IGF1R, SOX4, ALDH1, CD44, Cripto-1, OCT4, ARRB1, ARRB2, p-TFCP2L1, CDK1, DCLK1, and NANOG, which were all identified as CSC markers, have been implicated in the recurrence and metastasis of tumor in bladder cancer, which played a role as prognostic factor of bladder cancer. Given the pluripotent and highly proliferative properties of CSCs. CSCs may play a role in the complex biological behavior of bladder cancer, including, but not limited to, its high rates of recurrence, metastasis, and resistance to treatment. The detection of cancer stem cell markers offers a promising approach in determining the prognosis of bladder cancer. Further studies in this area are thus warranted and may contribute significantly to the overall management of bladder cancer.Cancer stem cells; Bladder cancer; Recurrency of bladder cancer; Metastasis of bladder cancer; Prognosis factor of bladder cancer
{"title":"The expression of cancer stem cells and its effects on the propensity for recurrence and metastasis in bladder cancer: a systematic review","authors":"Agus Rizal Ardy Hariandy Hamid, Yasmina Zahra Syadza, Oliver Emmanuel Yausep, Roberto Bagaskara Indy Christanto, Bayu Hernawan Rahmat Muharia, Chaidir Arif Mochtar","doi":"10.1101/2022.05.18.22275252","DOIUrl":"https://doi.org/10.1101/2022.05.18.22275252","url":null,"abstract":"Bladder cancer is one of the most frequent cancers of the urinary tract, associated with high recurrence rates and metastasis. Cancer stem cells (CSCs) are a subpopulation of cancer cells characterized by high self-renewal and differentiation capacities, resulting in increased cancer recurrence, larger tumor size, higher rates of metastasis, higher resistance to treatment, and overall poorer prognosis. This study aimed to evaluate the role of CSCs as a prognostic tool to predict the risks of metastasis and recurrence in bladder cancer. A literature search was conducted across seven databases from January 2000 to February 2022 for clinical studies investigating the use of CSCs to determine the prognosis of bladder cancer. The following keywords were used: (“Bladder Cancer” OR “Transitional Cell Carcinoma” OR “Urothelial Carcinoma”) AND (“Stem Cell” OR “Stem Gene”) AND (“Metastasis” OR “Recurrence”). A total of 12 studies were deemed eligible for inclusion. SOX2, IGF1R, SOX4, ALDH1, CD44, Cripto-1, OCT4, ARRB1, ARRB2, p-TFCP2L1, CDK1, DCLK1, and NANOG, which were all identified as CSC markers, have been implicated in the recurrence and metastasis of tumor in bladder cancer, which played a role as prognostic factor of bladder cancer. Given the pluripotent and highly proliferative properties of CSCs. CSCs may play a role in the complex biological behavior of bladder cancer, including, but not limited to, its high rates of recurrence, metastasis, and resistance to treatment. The detection of cancer stem cell markers offers a promising approach in determining the prognosis of bladder cancer. Further studies in this area are thus warranted and may contribute significantly to the overall management of bladder cancer.Cancer stem cells; Bladder cancer; Recurrency of bladder cancer; Metastasis of bladder cancer; Prognosis factor of bladder cancer","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138537729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
We summarized our experience regarding Transurethral Seminal Vesiculoscopy (TUSV) and analyzed both recurrence status and risk factors for recurrence. From January 2010 to December 2020, 48 patients with intractable hemospermia received successful TUSV at Taichung Invalids General Hospital. For the intraoperative findings, the five-year Disease-free Survival rates (DFS) were 74.1% in the no calculus group compared to 37.1% in the calculus group with a significant difference (log-rank p = 0.015), 75.0% in the no hemorrhage or no blood clot group compared to 43.2% in the hemorrhage or blood clot group with significant difference (log-rank p = 0.032). Univariate analysis showed intraoperative calculus (p = 0.040; HR: 2.94, 95% CI: 1.05–8.21) to be significantly associated with recurrence (p < 0.05). Patients with intractable hemospermia who were diagnosed with stones or blood clots found during TUSV experienced a higher rate of hemospermia recurrence.
我们总结了经尿道精囊镜检查(TUSV)的经验，并分析了复发情况和复发的危险因素。2010年1月至2020年12月，在台中荣民总医院对48例顽固性血精患者进行了成功的TUSV治疗。术中发现，无结石组5年无病生存率(DFS)为74.1%，结石组为37.1%，差异有统计学意义(log-rank p = 0.015);无出血或无血栓组为75.0%，出血或有血栓组为43.2%，差异有统计学意义(log-rank p = 0.032)。单因素分析显示术中结石(p = 0.040;HR: 2.94, 95% CI: 1.05-8.21)与复发显著相关(p <0.05)。顽固性血精症患者在TUSV期间被诊断为结石或血凝块，其血精症复发率较高。
{"title":"Intraoperative calculus or hemorrhage in transurethral seminal vesiculoscopy as a risk factor for recurrent hemospermia","authors":"Cheng-En Mei, Ju-Chuan Hu, Jian-Ri Li, Kun-Yuan Chiu, Shian-Shiang Wang, Chuan-Shu Chen","doi":"10.1101/2022.04.28.22274431","DOIUrl":"https://doi.org/10.1101/2022.04.28.22274431","url":null,"abstract":"We summarized our experience regarding Transurethral Seminal Vesiculoscopy (TUSV) and analyzed both recurrence status and risk factors for recurrence. From January 2010 to December 2020, 48 patients with intractable hemospermia received successful TUSV at Taichung Invalids General Hospital. For the intraoperative findings, the five-year Disease-free Survival rates (DFS) were 74.1% in the no calculus group compared to 37.1% in the calculus group with a significant difference (log-rank <em>p</em> = 0.015), 75.0% in the no hemorrhage or no blood clot group compared to 43.2% in the hemorrhage or blood clot group with significant difference (log-rank <em>p</em> = 0.032). Univariate analysis showed intraoperative calculus (<em>p</em> = 0.040; HR: 2.94, 95% CI: 1.05–8.21) to be significantly associated with recurrence (<em>p</em> < 0.05). Patients with intractable hemospermia who were diagnosed with stones or blood clots found during TUSV experienced a higher rate of hemospermia recurrence.","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138537723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-15DOI: 10.1101/2022.03.14.22272336
Ponco Birowo, Dimas Tri Prasetyo, Dwi Ari Pujianto, Widi Atmoko, Nur Rasyid
The impact of a low testosterone level among men with non-obstructive azoospermia with various testicular histopathological patterns on the regulation of glucose and lipid metabolism is less well known than among the general population. The aim of this retrospective study was to examine the association between testicular histopathology and components of the metabolic profile among men with non-obstructive azoospermia. Participants were divided into two groups: men with non-obstructive azoospermia and men with obstructive azoospermia. Testicular biopsies were performed among those with non-obstructive azoospermia. We included 115 patients in this study: 83 (72.2%) had non-obstructive azoospermia and 32 (27.8%) had obstructive azoospermia. The plasma glucose concentration, glycated hemoglobin level, and lipid profile were similar between patients with non-obstructive azoospermia and those with obstructive azoospermia. Upon subgroup analysis of patients with non-obstructive azoospermia, those with Sertoli-cell-only syndrome had the lowest testosterone (431 ± 238 ng/dL; P=0.039) and highest follicle-stimulating hormone (23.4 ± 18.2 mIU/mL; P=0.002) concentrations. They also had the highest triglyceride concentration (163 ± 114 mg/dL; P=0.001). Interestingly, patients with Sertoli-cell-only syndrome had a lower fasting plasma glucose concentration (92 ± 11 mg/dL; P<0.001) and glycated hemoglobin level (5.9 ± 0.8%; P=0.022) than those with histopathological patterns of maturation arrest and hypospermatogenesis. In conclusion, differences in glucose and lipid metabolism are evident between men with non-obstructive azoospermia with different spermatogenesis patterns.
{"title":"Glucose and lipid profiles in men with non-obstructive azoospermia","authors":"Ponco Birowo, Dimas Tri Prasetyo, Dwi Ari Pujianto, Widi Atmoko, Nur Rasyid","doi":"10.1101/2022.03.14.22272336","DOIUrl":"https://doi.org/10.1101/2022.03.14.22272336","url":null,"abstract":"The impact of a low testosterone level among men with non-obstructive azoospermia with various testicular histopathological patterns on the regulation of glucose and lipid metabolism is less well known than among the general population. The aim of this retrospective study was to examine the association between testicular histopathology and components of the metabolic profile among men with non-obstructive azoospermia. Participants were divided into two groups: men with non-obstructive azoospermia and men with obstructive azoospermia. Testicular biopsies were performed among those with non-obstructive azoospermia. We included 115 patients in this study: 83 (72.2%) had non-obstructive azoospermia and 32 (27.8%) had obstructive azoospermia. The plasma glucose concentration, glycated hemoglobin level, and lipid profile were similar between patients with non-obstructive azoospermia and those with obstructive azoospermia. Upon subgroup analysis of patients with non-obstructive azoospermia, those with Sertoli-cell-only syndrome had the lowest testosterone (431 ± 238 ng/dL; <em>P</em>=0.039) and highest follicle-stimulating hormone (23.4 ± 18.2 mIU/mL; <em>P=</em>0.002) concentrations. They also had the highest triglyceride concentration (163 ± 114 mg/dL; <em>P</em>=0.001). Interestingly, patients with Sertoli-cell-only syndrome had a lower fasting plasma glucose concentration (92 ± 11 mg/dL; <em>P</em><0.001) and glycated hemoglobin level (5.9 ± 0.8%; <em>P</em>=0.022) than those with histopathological patterns of maturation arrest and hypospermatogenesis. In conclusion, differences in glucose and lipid metabolism are evident between men with non-obstructive azoospermia with different spermatogenesis patterns.","PeriodicalId":501140,"journal":{"name":"medRxiv - Urology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138537718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：